Related Experiment Video

Updated: Jan 12, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.3K

Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma

Kazuhiko Sugiyama1, Yoshitaka Narita2, Motoo Nagane3

  • 1aDepartment of Clinical Oncology & Neuro-oncology Program, Hiroshima University Hospital.

Future Oncology (London, England)
|October 31, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BTKiBruton’s tyrosine kinase inhibitorONO-4059PCNSLprimary central nervous system lymphomatirabrutinib

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Experiment Videos

Last Updated: Jan 12, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.3K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

Risk and prognostic factors for intraprocedural rupture during endovascular treatment for unruptured intracranial aneurysm: Insights from JR-NET4.

AJNR. American journal of neuroradiology·2026

Working conditions, career barriers and perceived equity among neuro-oncology professionals: insights from the Japan society for neuro-oncology (JSNO) gender equality and diversity committee survey.

International journal of clinical oncology·2026

Rural medical disparities in multimodal glioblastoma treatment.

Scientific reports·2026

Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, of the adult cerebellum: a report of 2 cases.

Brain tumor pathology·2026

Preoperative prediction of meningioma grade based on synthetic MRI quantitative T1 and T2 mapping.

Japanese journal of radiology·2026

Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.

European journal of cancer (Oxford, England : 1990)·2026

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

Future oncology (London, England)·2026

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

Future oncology (London, England)·2026

PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.

Future oncology (London, England)·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

Future oncology (London, England)·2026

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Future oncology (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us